The current financial score of Journey Medical Corp is 8.94. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 18.51M, representing a year-over-year increase of 23.33%, while its net profit experienced a year-over-year increase of 91.78%.
The current valuation score of Journey Medical Corp is 9.10. Its current P/E ratio is -16.68, which is -378.41% below the recent high of 46.43 and -108.73% above the recent low of -34.81.
The current earnings forecast score of Journey Medical Corp is 8.00. The average price target is 14.50, with a high of 15.00 and a low of 14.00.
The current price momentum score of Journey Medical Corp is 4.47. Currently, the stock price is trading between the resistance level at 7.50 and the support level at 5.44, making it suitable for range-bound swing trading.
The current institutional shareholding score of Journey Medical Corp is 5.00. The latest institutional shareholding proportion is 56.62%, representing a quarter-over-quarter increase of 93.34%. The largest institutional shareholder is James Simons, holding a total of 229.70K shares, representing 0.00% of shares outstanding, with 5.36% increase in holdings.
The current risk assessment score of Journey Medical Corp is 3.31. The company's beta value is 1.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.